title: Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens.
abstract: The reactivity spectrum of three monoclonal antibodies (Mabs) to human malignant glioma, five Mabs to melanomas and one Mab anti-HLA-DR was investigated by an indirect antibody binding radioimmunoassay on a panel of cells derived from 60 glioma lines, including 47 malignant astrocytomas, 11 low-grade astrocytomas and two malignant ependymomas as well on cells from 12 melanoma, three neuroblastoma, three medulloblastoma, two schwannoma, two retinoblastoma, two choroïd plexus papilloma, ten meningioma and 12 unrelated tumor lines. The anti-glioma Mabs BF7 and GE2 reacted preferentially with gliomas, while the anti-glioma Mab CG12 reacted with gliomas, melanomas, neuroblastomas and medulloblastomas. The five anti-melanoma Mabs reacted with gliomas, neuroblastomas and medulloblastomas. The anti-HLA-DR Mab D1-12 reacted with gliomas, melanomas and some meningiomas. On the basis of the data presented, we describe three different antigenic systems; the first one is glioma-associated, the second one is related to differentiation antigens expressed on cells derived from the neuroectoderm and the third is represented by HLA-DR antigens which are expressed not only on B-lymphoblastoid cells but also on melanomas and gliomas.
authors.forename: B
authors.initials: B
authors.lastname: de Muralt
authors.forename: N
authors.initials: N
authors.lastname: de Tribolet
authors.forename: A C
authors.initials: AC
authors.lastname: Diserens
authors.forename: D
authors.initials: D
authors.lastname: Stavrou
authors.forename: J P
authors.initials: JP
authors.lastname: Mach
authors.forename: S
authors.initials: S
authors.lastname: Carrel
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis*; D002460:Cell Line; D005904:Glial Fibrillary Acidic Protein; D005910:Glioma / Q000276:immunology*; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000032:analysis*; D006801:Humans; D008545:Melanoma / Q000276:immunology*; D009363:Neoplasm Proteins / Q000032:analysis; D009380:Neoplasms, Nerve Tissue / Q000276:immunology*; D009419:Nerve Tissue Proteins / Q000032:analysis; D010641:Phenotype; D009418:S100 Proteins / Q000032:analysis
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D005904:Glial Fibrillary Acidic Protein; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D009418:S100 Proteins